Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy

BACKGROUND: Validation of biomarker‐based prognostic models to improve risk stratification in men with localized prostate cancer (PrCa) remains a clinical need. It has previously been shown that the cell cycle progression (CCP) test provides significant, independent prognostic information for men wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuzick, Jack M., Stone, Steven, Lenz, Lauren, Flake, Darl D., Rajamani, Saradha, Moller, Henrik, Berney, Daniel Maurice, Cohen, Todd, Scardino, Peter T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351676/
https://www.ncbi.nlm.nih.gov/pubmed/34423592
http://dx.doi.org/10.1002/cnr2.1535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351676/
https://www.ncbi.nlm.nih.gov/pubmed/34423592
http://dx.doi.org/10.1002/cnr2.1535

Ejemplares similares